Tanespimycin (17-AAG)

For research use only. Not for use in humans.

目录号：S1141 别名： CP127374,NSC-330507, KOS 953

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG)是一种有效的HSP90抑制剂，无细胞试验中IC50为5 nM，作用于来自肿瘤细胞的HSP90比作用于来自正常细胞HSP90结合亲和力高100倍。Tanespimycin (17-AAG)可诱导细胞凋亡、坏死、自噬和线粒体自噬。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2350.91 现货
RMB 795.18 现货
RMB 2432.97 现货
RMB 6527.43 现货
RMB 10950.03 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Tanespimycin (17-AAG)发表文献62篇：

产品安全说明书

HSP (e.g. HSP90)抑制剂选择性比较

生物活性

产品描述 Tanespimycin (17-AAG)是一种有效的HSP90抑制剂，无细胞试验中IC50为5 nM，作用于来自肿瘤细胞的HSP90比作用于来自正常细胞HSP90结合亲和力高100倍。Tanespimycin (17-AAG)可诱导细胞凋亡、坏死、自噬和线粒体自噬。Phase 2。
特性 17-AAG对正常细胞的毒性很小。
靶点
HSP90 [1]
(Cell-free assay)
5 nM
体外研究

17-AAG是格尔德霉素类似物, 但是与过量表达HER-2的癌细胞 (BT474, N87, SKOV3 和SKBR3)或BT474乳腺细胞衍生的Hsp90亲和力高100多倍，IC50为5-6 nM, 而作用于正常人类原代细胞时，IC50为400-943 nM, 因为肿瘤Hsp90 处于多伴复合体状态，具有高ATP酶活性，而正常细胞Hsp90 处于潜在未结合状态, 且直接与那些细胞中17-AAG毒性相关。[1]17-AAG 引起HER2, HER3, Akt，突变和野生型雄激素受体(AR)降解，导致前列腺细胞如LNCaP, LAPC-4, DU-145,和PC-3中RB依赖的 G1 期生长停顿，IC50为25-45 nM。[2]除了诱导改变野生型BCR-ABL的Ba/F3细胞凋亡, IC50为5.2 μM, 17-AAG还通过诱导野生型和突变型 BCR-ABL蛋白降解，而诱导改变抗 Imatinib Mesylate的 T315I和 E255K BCR-ABL突变型细胞生长，IC50分别为2.3 μM 和 1.0 μM。[3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIC3TlVKSzVyPUCuNFAxOzB|IN88US=> NWP3ZVRUW0GQR1XS
IST-MEL1 NFPNU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMECwOFA4KM7:TR?= NEfnNmpUSU6JRWK=
NCI-SNU-1 NEjkbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XOS2lEPTB;MD6wNFIxPyEQvF2= NXuwcYZvW0GQR1XS
FADU M17PXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljYTWM2OD1yLkCwNlA6KM7:TR?= NUj6NWx2W0GQR1XS
C32 NFrCdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzOdnZ[UUN3ME2wMlAxOzB2IN88US=> NWTSOnhvW0GQR1XS
D-566MG M4HNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzjT4liUUN3ME2wMlAxOzlizszN M{XGUXNCVkeHUh?=
LXF-289 M2DNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEToZ5ZKSzVyPUCuNFA1OTlizszN M3ztd3NCVkeHUh?=
HGC-27 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEC1NUDPxE1? M{fIV3NCVkeHUh?=
RPMI-7951 NY\SWmxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED2S|RKSzVyPUCuNFA4OTdizszN M2Pj[3NCVkeHUh?=
HSC-3 MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEC5Nlkh|ryP NIfUWIlUSU6JRWK=
MIA-PaCa-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK2TWM2OD1yLkCxNFA6KM7:TR?= MknKV2FPT0WU
KS-1 M{DEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHFTWM2OD1yLkCxN|U2KM7:TR?= Mne0V2FPT0WU
CAL-51 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[2TWM2OD1yLkCxOFA2KM7:TR?= MkjVV2FPT0WU
MDA-MB-361 NGfpWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMEG0PVUh|ryP NVHLb3ZTW0GQR1XS
TI-73 M{HOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;lZWlEPTB;MD6wNVc6PiEQvF2= MkHGV2FPT0WU
AGS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnnW4pkUUN3ME2wMlAyQTN6IN88US=> MnHEV2FPT0WU
NCI-H460 Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjielJKSzVyPUCuNFE6PzRizszN MUDTRW5ITVJ?
A204 M{ftOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\wSVBOUUN3ME2wMlAzOjR7IN88US=> MlTPV2FPT0WU
CHL-1 NUTm[JhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMEKyOVEh|ryP NILsXIpUSU6JRWK=
DU-4475 MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMEKyOlEh|ryP M{LoSXNCVkeHUh?=
CGTH-W-1 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XuVGlEPTB;MD6wNlM1QSEQvF2= MnTTV2FPT0WU
HCC2218 NFfJNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS4blhKSzVyPUCuNFI1QTRizszN MVHTRW5ITVJ?
A2780 M3ezbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\rU2lEPTB;MD6wNlU{OSEQvF2= M3;ZZXNCVkeHUh?=
NCI-H720 M4O5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEK1OFYh|ryP NXu4eZJ{W0GQR1XS
NCI-N87 NFfWe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMEK1PVMh|ryP MW\TRW5ITVJ?
CHP-212 NXvjSIF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7QTWM2OD1yLkCyOlI5KM7:TR?= NUDZcnBKW0GQR1XS
NCI-H23 M1n3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHEWIlKSzVyPUCuNFI3PjVizszN M2XkOHNCVkeHUh?=
D-263MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMEK3PFYh|ryP M3j3PHNCVkeHUh?=
ME-180 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEK4PVEh|ryP MlzvV2FPT0WU
SW982 NYnhfmx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjOdFBZUUN3ME2wMlAzQTl7IN88US=> Ml\KV2FPT0WU
OE19 NUTNS3dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEOwO|ch|ryP M3vEd3NCVkeHUh?=
SK-LU-1 NU\nTVFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWwTWM2OD1yLkCzNFgzKM7:TR?= NHzuT49USU6JRWK=
H4 NHv2[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfycmVmUUN3ME2wMlA{ODlizszN M3jrVXNCVkeHUh?=
HT-144 MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMEOwPVMh|ryP NWDnc4pkW0GQR1XS
SK-UT-1 M4X2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLySYFkUUN3ME2wMlA{OTd6IN88US=> NVzUbFhEW0GQR1XS
D-336MG NYXmU5F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3wTWM2OD1yLkCzN|A6KM7:TR?= M4jVV3NCVkeHUh?=
MDA-MB-175-VII NHXaR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjq[JVKSzVyPUCuNFM{PTRizszN NHft[VVUSU6JRWK=
GAMG MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXZWZNpUUN3ME2wMlA{PDN3IN88US=> Ml7lV2FPT0WU
CP50-MEL-B NH[zdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTWTWM2OD1yLkCzOFUh|ryP MX3TRW5ITVJ?
OVCAR-5 NHrvR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnNfG5JUUN3ME2wMlA{PDhizszN MlHzV2FPT0WU
SK-MES-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XuWWlEPTB;MD6wN|YxPiEQvF2= NIDzVWNUSU6JRWK=
VM-CUB-1 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HB[2lEPTB;MD6wN|Y2PyEQvF2= MojwV2FPT0WU
WM-115 M1XSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfzd4lKSzVyPUCuNFM4PjJizszN NXXzfIU3W0GQR1XS
DSH1 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMEO4NFch|ryP NEH5O45USU6JRWK=
Becker NX;yd41ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml25TWM2OD1yLkCzPFg2KM7:TR?= NGnhSG5USU6JRWK=
SW962 M3GyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W4fWlEPTB;MD6wN|k1PSEQvF2= NX7F[JNEW0GQR1XS
TYK-nu NF;QO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnDdGVmUUN3ME2wMlA{QTh3IN88US=> NGjQV4tUSU6JRWK=
HO-1-N-1 MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\xTWM2OD1yLkC0NFIyKM7:TR?= NFWwZVlUSU6JRWK=
T98G MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG2[m9KSzVyPUCuNFQyODNizszN NWD5enNLW0GQR1XS
ACN NY\ZcIo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XXTGlEPTB;MD6wOFE3OiEQvF2= MoP1V2FPT0WU
SW780 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki0TWM2OD1yLkC0NlA{KM7:TR?= NIPrd2JUSU6JRWK=
Detroit562 NIXqfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;zNZNKSzVyPUCuNFQzOzlizszN NWPDXZY4W0GQR1XS
BB49-HNC NFjubZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS0TWM2OD1yLkC0NlQ{KM7:TR?= MoT6V2FPT0WU
HN MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMESyO|Ih|ryP NGPrV4pUSU6JRWK=
H9 NGqzUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjTdJdJUUN3ME2wMlA1OzdzIN88US=> M2DyenNCVkeHUh?=
VA-ES-BJ M3q5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnqTWM2OD1yLkC0OFQ4KM7:TR?= NID5dlNUSU6JRWK=
MEL-JUSO NHLWW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwMES0O|Uh|ryP M4TP[3NCVkeHUh?=
BT-474 M2CyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnNPHhWUUN3ME2wMlA1PSEQvF2= M4\lRXNCVkeHUh?=
CaR-1 NGnxfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLjdVF2UUN3ME2wMlA1PTR7IN88US=> M{XMbHNCVkeHUh?=
PSN1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nudGlEPTB;MD6wOFYxOyEQvF2= MWjTRW5ITVJ?
KYSE-510 NGTzNZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e5PWlEPTB;MD6wOFY1QSEQvF2= NYPqT3lGW0GQR1XS
KP-4 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP5cYdXUUN3ME2wMlA1PzV|IN88US=> NIDjR49USU6JRWK=
KYSE-410 M3WwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zrXmlEPTB;MD6wOFc4OiEQvF2= M3\vT3NCVkeHUh?=
G-402 NGTobYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuySFFKSzVyPUCuNFQ4QDlizszN NWnvc4JTW0GQR1XS
DOK MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTaXmlCUUN3ME2wMlA1QTB{IN88US=> M{DPdHNCVkeHUh?=
COR-L88 M4SwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLwSZRZUUN3ME2wMlA1QTF{IN88US=> MlWwV2FPT0WU
SKG-IIIa NHnwXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HyVWlEPTB;MD6wOFk5PiEQvF2= MV;TRW5ITVJ?
AN3-CA Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEWg{txO MX3TRW5ITVJ?
SW48 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrQTWM2OD1yLkC1NFM6KM7:TR?= MVjTRW5ITVJ?
YKG-1 NYrPd2w1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y4d2lEPTB;MD6wOVA4OSEQvF2= M3\XRXNCVkeHUh?=
KYSE-150 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMEWyN|Uh|ryP NXvnTXZrW0GQR1XS
HuO-3N1 NHLZOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Xk[mlEPTB;MD6wOVI{PyEQvF2= M4fzV3NCVkeHUh?=
LB1047-RCC NH70enNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jRTmlEPTB;MD6wOVI6PiEQvF2= MkjyV2FPT0WU
NCI-H2030 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPHTWM2OD1yLkC1OFE1KM7:TR?= MmO0V2FPT0WU
YH-13 NVXlTZV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEW3NlIh|ryP MVjTRW5ITVJ?
5637 NWj4cWJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X4[2lEPTB;MD6wOVc1KM7:TR?= M3zY[3NCVkeHUh?=
LOXIMVI NUK5O5F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMEW4O|Ih|ryP M1nBPXNCVkeHUh?=
GT3TKB M{fXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorPTWM2OD1yLkC1PVQzKM7:TR?= NFPTTG5USU6JRWK=
TCCSUP MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEW5OlQh|ryP MlHSV2FPT0WU
EPLC-272H MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwME[yNFUh|ryP NFv2N2tUSU6JRWK=
LU-99A MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH1TWM2OD1yLkC2NlM4KM7:TR?= NEHPbmJUSU6JRWK=
NCI-H1755 NHzLTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofITWM2OD1yLkC2N|QyKM7:TR?= MVvTRW5ITVJ?
KM12 NUfXUYF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwME[zOFgh|ryP Mm\2V2FPT0WU
SF295 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwME[0OVIh|ryP M1ntNXNCVkeHUh?=
MZ2-MEL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jlOmlEPTB;MD6wOlU2OyEQvF2= NFjkWWtUSU6JRWK=
HEC-1 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwME[1PFgh|ryP NIi4e3dUSU6JRWK=
SW684 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\0ZXRkUUN3ME2wMlA3PTlzIN88US=> NGPzZ2hUSU6JRWK=
SF539 NYDEWoRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTsb|J[UUN3ME2wMlA3PjhzIN88US=> MVHTRW5ITVJ?
GMS-10 NV25T4pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\peWlEPTB;MD6wOlY6QSEQvF2= NFjhSXBUSU6JRWK=
MV-4-11 NW\BUZlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPuTWM2OD1yLkC2PFA{KM7:TR?= MUnTRW5ITVJ?
HT-29 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjTe5BKSzVyPUCuNFY6OTlizszN MknyV2FPT0WU
23132-87 NILSd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrTcIVCUUN3ME2wMlA3QTVizszN M4fUSXNCVkeHUh?=
SW620 NXjacYh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\wS25KSzVyPUCuNFcxOjZizszN NFm2[JpUSU6JRWK=
HCC1806 NVfE[I5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMEexN|Eh|ryP NGDQTVFUSU6JRWK=
Hs-578-T M1j2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfmTWM2OD1yLkC3NlA5KM7:TR?= MojFV2FPT0WU
A2058 NWP2cFJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;q[lNxUUN3ME2wMlA4OjJ6IN88US=> M33VVnNCVkeHUh?=
MEL-HO NHjTW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XXV2lEPTB;MD6wO|I2PSEQvF2= M3HtdXNCVkeHUh?=
HCC2998 NI\ud5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTQTWM2OD1yLkC3N|Q4KM7:TR?= NELDeZJUSU6JRWK=
HuO9 MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHvSnRKSzVyPUCuNFc2QDlizszN M3XLVHNCVkeHUh?=
CAL-39 M3HV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMEe3OlYh|ryP NVjIe3hrW0GQR1XS
M14 NYTRU4JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T3eGlEPTB;MD6wO|kyOyEQvF2= NF60fVVUSU6JRWK=
BFTC-909 M2K1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEe5Olkh|ryP MU\TRW5ITVJ?
TE-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ywWmlEPTB;MD6wO|k6PiEQvF2= NUHoVGZvW0GQR1XS
TGBC1TKB NIDtOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm0U256UUN3ME2wMlA5ODR|IN88US=> MlrYV2FPT0WU
L-363 NY\lR3l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjIOHkzUUN3ME2wMlA5OjB4IN88US=> Ml\tV2FPT0WU
A431 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrmTWM2OD1yLkC4NlEh|ryP NYq1NnRiW0GQR1XS
MKN45 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\CR4twUUN3ME2wMlA5OjF7IN88US=> MnHsV2FPT0WU
HT-1080 NXq2OFROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMEi0N|kh|ryP NUf2WVdmW0GQR1XS
OVCAR-8 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HBOmlEPTB;MD6wPFYzOiEQvF2= MlLGV2FPT0WU
LCLC-97TM1 NF75Z2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfqbnV6UUN3ME2wMlA5PzJ6IN88US=> MlfLV2FPT0WU
M059J NHyzVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES4c3pKSzVyPUCuNFkxOjdizszN MkPJV2FPT0WU
SK-MEL-2 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTZTWM2OD1yLkC5NFYh|ryP MnLGV2FPT0WU
TE-1 NH;yXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G0XmlEPTB;MD6wPVIxPCEQvF2= NI\IVYlUSU6JRWK=
KYSE-180 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEmyOlIh|ryP NFq0WXpUSU6JRWK=
D-247MG NIr6TWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzRUWdKSzVyPUCuNFk1PTVizszN M3jsc3NCVkeHUh?=
8-MG-BA MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEm0O|Ih|ryP NVrhdZVZW0GQR1XS
NCI-H1792 NIjHWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHITWM2OD1yLkC5OlE5KM7:TR?= M3vSSHNCVkeHUh?=
MCF7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f1cWlEPTB;MD6wPVY4PyEQvF2= MXTTRW5ITVJ?
NCI-H2122 M2fvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;sVGlEPTB;MD6wPVc1PSEQvF2= NFzwbHVUSU6JRWK=
EFO-27 M2TNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMEm5PVch|ryP NV;4TXVGW0GQR1XS
LB2241-RCC M4jUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMUCwOVQh|ryP NIi2ZmRUSU6JRWK=
SN12C NULhOXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMUCxNFch|ryP MWTTRW5ITVJ?
A498 M4TSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMUCxPEDPxE1? NEjWTVZUSU6JRWK=
PANC-03-27 NFLWV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\1O4FKSzVyPUCuNVAzQDZizszN MYTTRW5ITVJ?
NCI-H1581 M4nmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfC[WFKSzVyPUCuNVAzQSEQvF2= NWflbYdyW0GQR1XS
U-87-MG MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TLb2lEPTB;MD6xNFMxPyEQvF2= NV7zZXhVW0GQR1XS
G-401 NFy0c5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4POW2lEPTB;MD6xNFM2OyEQvF2= M2\PUHNCVkeHUh?=
SiHa Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zqe2lEPTB;MD6xNFQ5PiEQvF2= M{D2V3NCVkeHUh?=
U251 NXixVmhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMUC1NlUh|ryP NV\WV2l2W0GQR1XS
MMAC-SF NV;RdnN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnLUmRRUUN3ME2wMlExPTNzIN88US=> NYfSV|VKW0GQR1XS
BB65-RCC NYH0VHpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{noPWlEPTB;MD6xNFU2PCEQvF2= MnjhV2FPT0WU
NKM-1 M1zyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHyXZRpUUN3ME2wMlExPjZ4IN88US=> M4K1WnNCVkeHUh?=
HD-MY-Z MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTT[VFxUUN3ME2wMlExQDd|IN88US=> NF;HSmJUSU6JRWK=
TGBC11TKB M{W2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojZTWM2OD1yLkGwPVA{KM7:TR?= NYO0Onk3W0GQR1XS
COLO-679 NVSwUJBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrTNFV2UUN3ME2wMlEyOjFzIN88US=> M3nTVHNCVkeHUh?=
TE-8 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqzSHZRUUN3ME2wMlEyOjZ2IN88US=> MnLCV2FPT0WU
SK-MEL-28 Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELhR3RKSzVyPUCuNVE{OjFizszN NXzRcW97W0GQR1XS
SH-4 NHnvbodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHIdHFtUUN3ME2wMlEyOzV4IN88US=> NIPLd2VUSU6JRWK=
KALS-1 NFLudFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XRNWlEPTB;MD6xNVM6OyEQvF2= MlrZV2FPT0WU
RKO MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLRTWM2OD1yLkGxO|Y1KM7:TR?= M4LJWXNCVkeHUh?=
OMC-1 Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMUG3PVch|ryP M2r3V3NCVkeHUh?=
BT-549 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvHTWM2OD1yLkGxO|k6KM7:TR?= MVXTRW5ITVJ?
NCI-H28 NUDaUXNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fiV2lEPTB;MD6xNVgyPyEQvF2= MVrTRW5ITVJ?
RXF393 NG\3cZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMUG5PFIh|ryP NETFNINUSU6JRWK=
COLO-829 NXXJ[GFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMUKwNFUh|ryP MUnTRW5ITVJ?
HMV-II MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PDd2lEPTB;MD6xNlAzKM7:TR?= NGLQXZhUSU6JRWK=
SW1990 MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1raO2lEPTB;MD6xNlE2PyEQvF2= MnHtV2FPT0WU
NCI-H1437 NXTJfWJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjuTWM2OD1yLkGyNVU4KM7:TR?= MWPTRW5ITVJ?
SNB75 M4PBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMUKxOlkh|ryP NF;KRolUSU6JRWK=
EW-3 NUPk[VZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LMT2lEPTB;MD6xNlY3OSEQvF2= Mn6xV2FPT0WU
SAS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMUK2PUDPxE1? M3LKVHNCVkeHUh?=
NCI-H1666 NG\yV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TIUmlEPTB;MD6xNlc4PCEQvF2= M3Lp[nNCVkeHUh?=
A375 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCzRmNKSzVyPUCuNVI4PzhizszN NWXMeGhyW0GQR1XS
CAMA-1 NW\hUmQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[5SmJKSzVyPUCuNVI6OjRizszN NF\RVpJUSU6JRWK=
HuP-T4 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMUK5OFMh|ryP NXrHN2JoW0GQR1XS
NCI-H292 M2nvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzFVFMyUUN3ME2wMlE{OTFizszN M4m4TXNCVkeHUh?=
PC-14 NWLrXopNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWyXmJKSzVyPUCuNVMzOTFizszN NVXiZ2lIW0GQR1XS
BPH-1 M1zzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[3TWM2OD1yLkGzOFEh|ryP NFnYSoxUSU6JRWK=
GAK MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvkeoY1UUN3ME2wMlE{PTZ5IN88US=> MXfTRW5ITVJ?
VMRC-RCZ NXnoXJdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjQTFNKSzVyPUCuNVM4PjJizszN M4TPS3NCVkeHUh?=
SK-MEL-24 M4XIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTac|FjUUN3ME2wMlE{QDdizszN MkTrV2FPT0WU
LB831-BLC Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIriTZBKSzVyPUCuNVM5QDNizszN NF7JTYxUSU6JRWK=
NCI-H2452 M1y1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzzdJdKSzVyPUCuNVM6PTZizszN M1L0[nNCVkeHUh?=
RT-112 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMUSwN|Uh|ryP NWC2eWZGW0GQR1XS
GP5d NXToUJh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jpNGlEPTB;MD6xOFExPCEQvF2= MX;TRW5ITVJ?
LC-2-ad NFW0fXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMUSxNlEh|ryP M1riR3NCVkeHUh?=
MPP-89 NH34VFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S3[GlEPTB;MD6xOFEzPSEQvF2= NHnONGtUSU6JRWK=
NUGC-3 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\ETWM2OD1yLkG0OFc5KM7:TR?= MkfVV2FPT0WU
GI-1 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz4TWM2OD1yLkG0OVU5KM7:TR?= Ml;6V2FPT0WU
HCC1419 M2PBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\rengyUUN3ME2wMlE1PTd4IN88US=> M4L3NXNCVkeHUh?=
SW1573 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nhbGlEPTB;MD6xOFc2QCEQvF2= NGDnfGlUSU6JRWK=
NCI-H2347 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vqcWlEPTB;MD6xOFg{QSEQvF2= MWfTRW5ITVJ?
Mewo MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;lVopKSzVyPUCuNVQ5QDlizszN NVe3e2lrW0GQR1XS
639-V NWHwc5F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjjW|duUUN3ME2wMlE2ODF|IN88US=> MnXtV2FPT0WU
AsPC-1 MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMUWyNlUh|ryP NUD4W4N5W0GQR1XS
NCI-H1648 M1zTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnORWJKSzVyPUCuNVUzOzJizszN MYLTRW5ITVJ?
786-0 M1;XTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3YTWM2OD1yLkG1N|gyKM7:TR?= NFnXV2lUSU6JRWK=
ETK-1 NVqxXYt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zycGlEPTB;MD6xOVkh|ryP M4X3OnNCVkeHUh?=
BxPC-3 M2Hyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSwTWM2OD1yLkG1PVY3KM7:TR?= M1rmeXNCVkeHUh?=
CAL-62 NXfEcYlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;hdYNKSzVyPUCuNVYyPjlizszN MV7TRW5ITVJ?
HCC1937 NXmzVGk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrpNFhyUUN3ME2wMlE3Ojd3IN88US=> NXWyepZzW0GQR1XS
NCI-H1299 NVXt[5BST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFn0bm1KSzVyPUCuNVYzQDVizszN NFe3XmlUSU6JRWK=
SW1088 MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\iOmxMUUN3ME2wMlE3PDF|IN88US=> MVXTRW5ITVJ?
FTC-133 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMU[1OEDPxE1? MYTTRW5ITVJ?
OC-314 M3q5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMU[2PUDPxE1? MoTBV2FPT0WU
SCC-9 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\6dIlKSzVyPUCuNVY4OTZizszN M2HqbnNCVkeHUh?=
HT-1376 NU\qXHBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2noZ2lEPTB;MD6xOlk{PiEQvF2= NV\vUIdkW0GQR1XS
U-2-OS NGjYfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXKTWM2OD1yLkG3NVc{KM7:TR?= NUfCS4VmW0GQR1XS
COLO-824 M{PKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPtN5BKSzVyPUCuNVczQTRizszN M1u0PXNCVkeHUh?=
BB30-HNC M2PWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXIXI5HUUN3ME2wMlE4OzNizszN MmXYV2FPT0WU
NCI-H2087 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn5fW5qUUN3ME2wMlE4OzZ6IN88US=> NFfVToRUSU6JRWK=
NCI-H2170 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKxTWM2OD1yLkG3OVM3KM7:TR?= M4rCdHNCVkeHUh?=
SK-OV-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G4O2lEPTB;MD6xO|U4OSEQvF2= NEfMdllUSU6JRWK=
MZ7-mel NHLVOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMUe2OFkh|ryP NWX3eoFJW0GQR1XS
NCI-H650 Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[we|l1UUN3ME2wMlE4Pjh{IN88US=> MYLTRW5ITVJ?
KOSC-2 M13MRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMUe3N|Qh|ryP MnfyV2FPT0WU
SCC-4 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMUe3O|ch|ryP M4LWUXNCVkeHUh?=
MDA-MB-157 M2HnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrnTWM2OD1yLkG4NFgzKM7:TR?= M2fYd3NCVkeHUh?=
KYSE-520 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfrdWZKSzVyPUCuNVgzKM7:TR?= MXzTRW5ITVJ?
LK-2 M4j2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfDSmtwUUN3ME2wMlE5OzB|IN88US=> Mn7CV2FPT0WU
KNS-81-FD NEXiOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4mwVGlEPTB;MD6xPFM6PCEQvF2= MXrTRW5ITVJ?
IGROV-1 M{\ROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r1eGlEPTB;MD6xPFQ1OyEQvF2= MUHTRW5ITVJ?
DEL MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13nRmlEPTB;MD6xPFQ2KM7:TR?= Mn:1V2FPT0WU
NCI-H1395 M1nP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:0UWlEPTB;MD6xPFY5OiEQvF2= MnXLV2FPT0WU
JEG-3 M1vHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHLTWM2OD1yLkG4O|A2KM7:TR?= MnnhV2FPT0WU
BCPAP MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTmTWM2OD1yLkG4PFczKM7:TR?= MUHTRW5ITVJ?
CAL-27 MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1riS2lEPTB;MD6xPVAzOiEQvF2= MWXTRW5ITVJ?
RD MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zYRWlEPTB;MD6xPVEyOyEQvF2= NXrUXVE5W0GQR1XS
RVH-421 NXrC[2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMUmxNVYh|ryP M2qxZnNCVkeHUh?=
Capan-2 Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XoSGlEPTB;MD6xPVI2PiEQvF2= MnPKV2FPT0WU
COLO-680N MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDN[JJKSzVyPUCuNVk{PjRizszN NF3zXXZUSU6JRWK=
NCI-H1650 M1\RbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXSTWM2OD1yLkKwNFU4KM7:TR?= MnewV2FPT0WU
SBC-5 M3zYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\oTWdKSzVyPUCuNlAyOThizszN NILRS3RUSU6JRWK=
U031 NHrTWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMkC1OFch|ryP NYTpZ3JMW0GQR1XS
S-117 NXLnUZd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjUTWM2OD1yLkKwOVY1KM7:TR?= MWLTRW5ITVJ?
DoTc2-4510 M{DxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMkC3Olkh|ryP NGXkV4JUSU6JRWK=
AM-38 NFm1e5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMkC4OFgh|ryP MXzTRW5ITVJ?
A172 NYXKS3pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPlNoNKSzVyPUCuNlExOjJizszN MUDTRW5ITVJ?
HPAF-II M2DKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK3SnBKSzVyPUCuNlEzPjRizszN MWfTRW5ITVJ?
769-P MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMkGyPEDPxE1? Mof4V2FPT0WU
MFE-280 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMkGyPVgh|ryP M{PXSHNCVkeHUh?=
TE-9 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrnTWM2OD1yLkKxO|g3KM7:TR?= MV;TRW5ITVJ?
C2BBe1 NXztNmxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDxWno6UUN3ME2wMlIzOTlizszN NVOyVnhVW0GQR1XS
EoL-1-cell MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jBSGlEPTB;MD6yNlIxOyEQvF2= MkXIV2FPT0WU
G-361 NWrvVVBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFuwXZBKSzVyPUCuNlI3QDJizszN MVjTRW5ITVJ?
KYSE-270 NEPqSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf0RVhKSzVyPUCuNlMxQDRizszN M{eyTXNCVkeHUh?=
TK10 NYe5V3dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HEdWlEPTB;MD6yN|EyPyEQvF2= NFG5SHlUSU6JRWK=
ML-2 M4PPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPkTWM2OD1yLkKzNVE6KM7:TR?= MnixV2FPT0WU
MHH-ES-1 NEL1[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMkO2PFEh|ryP NF;FNpJUSU6JRWK=
BHY NYPLPWk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTUOGl2UUN3ME2wMlI{PjlzIN88US=> MWHTRW5ITVJ?
LS-513 NUHvNoNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;aWWVVUUN3ME2wMlI{QTZzIN88US=> MU\TRW5ITVJ?
COLO-678 M4nOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHMeHdKSzVyPUCuNlQxPDRizszN NWfKTZd2W0GQR1XS
NCI-H747 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTRdW5KSzVyPUCuNlQyPjlizszN MnnZV2FPT0WU
K5 M3TUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLCTWM2OD1yLkK0N|gh|ryP MoPKV2FPT0WU
OS-RC-2 M4rVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi2ZXhCUUN3ME2wMlI1PTB7IN88US=> NXvTVVhWW0GQR1XS
KINGS-1 M4PJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ezSmlEPTB;MD6yOFUzQSEQvF2= NWnvNY9LW0GQR1XS
SCC-25 M4fweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnPenVrUUN3ME2wMlI1PTZ|IN88US=> NUn4SnpyW0GQR1XS
CAPAN-1 MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfrcZVtUUN3ME2wMlI1Pzh|IN88US=> NH;EcG1USU6JRWK=
ESS-1 NHP2[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXObpFKSzVyPUCuNlQ5ODVizszN Mnv3V2FPT0WU
TE-6 NYnKV2VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP3UZlEUUN3ME2wMlI2PzVizszN NWHYXmJmW0GQR1XS
LB2518-MEL MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzTVFFSUUN3ME2wMlI2Pzd5IN88US=> NHjwTnFUSU6JRWK=
COLO-800 NXywRXl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMkW4NVIh|ryP NGXFb5hUSU6JRWK=
LU-134-A NIT1Z3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT0TWM2OD1yLkK2NVM3KM7:TR?= Ml76V2FPT0WU
NCI-H1155 NXW0boFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\vTWM2OD1yLkK2NVYzKM7:TR?= NWrmXoZ3W0GQR1XS
MFM-223 NUjIdWNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jrbGlEPTB;MD6yOlM3OyEQvF2= NX;HVZVPW0GQR1XS
HTC-C3 MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O2O2lEPTB;MD6yOlUxPiEQvF2= NIm0endUSU6JRWK=
HCT-116 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HrbGlEPTB;MD6yOlU6QSEQvF2= MVHTRW5ITVJ?
Ca-Ski NYDCXXVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrWOnpKSzVyPUCuNlY3PzhizszN M2HrNXNCVkeHUh?=
SBC-1 NFzUSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnzV5k3UUN3ME2wMlI3PzR{IN88US=> NH73b4lUSU6JRWK=
NB69 MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfKbZBKSzVyPUCuNlcxQDdizszN M4XiVHNCVkeHUh?=
J82 NXLzUJNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\sdoc3UUN3ME2wMlI4OjZ3IN88US=> MnPXV2FPT0WU
U-118-MG MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLWTWM2OD1yLkK3OVc6KM7:TR?= M4rKZnNCVkeHUh?=
NCI-H1355 NX\Ib3cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLhTWM2OD1yLkK4NFc1KM7:TR?= NWSw[2w1W0GQR1XS
NCI-H1048 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHEUplWUUN3ME2wMlI5QTV4IN88US=> MYTTRW5ITVJ?
SW954 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS0ZXdKSzVyPUCuNlkzOjdizszN M2n6bnNCVkeHUh?=
NMC-G1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17aWmlEPTB;MD6yPVI4PyEQvF2= NWHqO2piW0GQR1XS
SW1710 NIjufHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDUWXB6UUN3ME2wMlI6PDl2IN88US=> NUm5OHVNW0GQR1XS
KY821 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnZPG9KSzVyPUCuNlk5PzJizszN NHXu[oFUSU6JRWK=
HCC38 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO3TWM2OD1yLkOwNFc5KM7:TR?= MUTTRW5ITVJ?
NCI-SNU-5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fkcmlEPTB;MD6zNFU1KM7:TR?= NUjaZ21NW0GQR1XS
ES8 NV24dJQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3SVYFKSzVyPUCuN|A4QDRizszN MY\TRW5ITVJ?
COLO-792 Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwM{GyOVEh|ryP MXrTRW5ITVJ?
BFTC-905 M1rT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITZS4tKSzVyPUCuN|E2OjFizszN M2jm[nNCVkeHUh?=
ChaGo-K-1 M37BeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XNbWlEPTB;MD6zNVcyPSEQvF2= MnL2V2FPT0WU
Daoy MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwM{G3NlMh|ryP NVG2TJBvW0GQR1XS
SJSA-1 NFHBUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLae5ZKSzVyPUCuN|E5PDdizszN MmjSV2FPT0WU
KNS-62 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTzZ5RMUUN3ME2wMlMzODh6IN88US=> M2LGXnNCVkeHUh?=
CAKI-1 MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq1fmFEUUN3ME2wMlMzOTFzIN88US=> MV3TRW5ITVJ?
UACC-62 NEPXWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXrPWZKSzVyPUCuN|IzOjdizszN NUXlT4VmW0GQR1XS
HuCCT1 NVjabpVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwM{KyPFMh|ryP NWq0TFl2W0GQR1XS
CTB-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjmTWM2OD1yLkOyO|U{KM7:TR?= Mn2zV2FPT0WU
NTERA-S-cl-D1 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\rfWlEPTB;MD6zNlg{PiEQvF2= NIT6RWFUSU6JRWK=
T-24 M2SzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwM{OxOVkh|ryP MV\TRW5ITVJ?
KYSE-70 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwM{OyPFMh|ryP NWXkfmhZW0GQR1XS
SW626 Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[yeI5tUUN3ME2wMlM{PTN{IN88US=> NWnpUZVwW0GQR1XS
LB996-RCC NG\STplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\GXmJQUUN3ME2wMlM{PjF7IN88US=> NF;IVZBUSU6JRWK=
DMS-273 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PzeWlEPTB;MD6zN|kyPiEQvF2= NF3Kc4xUSU6JRWK=
SW1783 M{P3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LHWGlEPTB;MD6zN|k6PyEQvF2= MnjBV2FPT0WU
KU812 NHTIT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfLOXhKSzVyPUCuN|QxOzhizszN NFfOTppUSU6JRWK=
HSC-2 NIjKZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXDTWM2OD1yLkO0NFU{KM7:TR?= M1S1TnNCVkeHUh?=
A3-KAW NHTJO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XGUGlEPTB;MD6zOFE3OiEQvF2= NV7mR2JvW0GQR1XS
COLO-684 M{TIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELUOJBKSzVyPUCuN|Q2ODFizszN MVLTRW5ITVJ?
NCI-H2405 NGXoSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwM{S2N|Eh|ryP M2i5SnNCVkeHUh?=
NCI-H2228 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\JSHE4UUN3ME2wMlM2OzV5IN88US=> NEn4[49USU6JRWK=
NB13 M3u1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;FTWM2OD1yLkO2PFI6KM7:TR?= NFfjc3dUSU6JRWK=
no-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH3SG94UUN3ME2wMlM3QTVizszN MYTTRW5ITVJ?
DK-MG MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz5NnQ4UUN3ME2wMlM4OTh6IN88US=> M3nNenNCVkeHUh?=
NBsusSR MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwM{eyPFUh|ryP NGnORWFUSU6JRWK=
KP-N-YS MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H2e2lEPTB;MD6zO|Q3OyEQvF2= NV3mbIdOW0GQR1XS
CFPAC-1 NEPMSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDrTWM2OD1yLkO3OVE5KM7:TR?= MUnTRW5ITVJ?
KARPAS-45 NV3IZoRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHXZWFrUUN3ME2wMlM4QDZ{IN88US=> MXTTRW5ITVJ?
NCI-H1793 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz3ZnY1UUN3ME2wMlM5PTFizszN MnTQV2FPT0WU
HCE-T NGKx[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLUfZdKSzVyPUCuN|g3ODNizszN NXT1coVCW0GQR1XS
NCI-H520 M3PpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP1TWM2OD1yLkO4O|A{KM7:TR?= Mo\qV2FPT0WU
HCC2157 NGHGNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjBTWM2OD1yLkO4O|gyKM7:TR?= NGTNW2tUSU6JRWK=
EW-18 M{DqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDYOW5RUUN3ME2wMlM5QTRzIN88US=> NYj1eG9[W0GQR1XS
RO82-W-1 M{naR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XDWGlEPTB;MD6zPVY6QSEQvF2= NUO5XpNIW0GQR1XS
HuP-T3 NE[4dIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\vW2lEPTB;MD60NFE1OyEQvF2= NWDIeVM2W0GQR1XS
PANC-10-05 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjpTJdKSzVyPUCuOFEyPyEQvF2= MmTuV2FPT0WU
NCI-H1703 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HENGlEPTB;MD60NVQ1PiEQvF2= M3jYVnNCVkeHUh?=
TE-10 NWCzc|lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jo[WlEPTB;MD60NVQ1PyEQvF2= NF\SUpBUSU6JRWK=
HOS NXHweJhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TTc2lEPTB;MD60NVY5OiEQvF2= MWjTRW5ITVJ?
LN-405 M1[3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwNEG2PFch|ryP NFPNUW5USU6JRWK=
A427 NFfDdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[ybXB1UUN3ME2wMlQyQThzIN88US=> M3XZN3NCVkeHUh?=
CAL-12T MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTVTWM2OD1yLkSyO|gh|ryP NFPCSJhUSU6JRWK=
SW756 M{jGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\KZXBKSzVyPUCuOFQyQDNizszN MW\TRW5ITVJ?
YAPC M3P4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jweWlEPTB;MD60OVA5KM7:TR?= NVTYZmxwW0GQR1XS
GOTO M4fDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHqSlBKSzVyPUCuOFUyPiEQvF2= M{D4TXNCVkeHUh?=
C3A M{T4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwNEW0N|ch|ryP MlzMV2FPT0WU
UM-UC-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHo[ZdKSzVyPUCuOFU1PyEQvF2= NVfHcWlUW0GQR1XS
NCI-H1573 M3yxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe4XW5JUUN3ME2wMlQ2PTZ7IN88US=> MnvQV2FPT0WU
LS-411N NWn6cIFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwNE[1Nlch|ryP MkLNV2FPT0WU
COR-L23 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTmTWM2OD1yLkS2O|Y1KM7:TR?= MkfHV2FPT0WU
HCE-4 NH7hdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXhfIpRUUN3ME2wMlQ4PDR4IN88US=> NVizZpdCW0GQR1XS
NCI-H2291 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT1XJVrUUN3ME2wMlQ4QDl4IN88US=> MnXqV2FPT0WU
A101D M2\hT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwNEiwOVMh|ryP MoHlV2FPT0WU
HT-3 MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHKTY9KSzVyPUCuOFgzOTdizszN MVTTRW5ITVJ?
HOP-62 NFnP[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwNEm4OlUh|ryP MUnTRW5ITVJ?
PC-3 M3n6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwNUG1NFch|ryP MkfBV2FPT0WU
CTV-1 NH\tXo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzqTWM2OD1yLkWyOlY6KM7:TR?= Mo\WV2FPT0WU
PANC-08-13 M1T5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlziTWM2OD1yLkWzNVc4KM7:TR?= MV\TRW5ITVJ?
CAL-120 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwNUOzPVkh|ryP Mn7tV2FPT0WU
UMC-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwNUWyN|Qh|ryP NHK1R4FUSU6JRWK=
MSTO-211H NF;tUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWftZ2x7UUN3ME2wMlU2PzZ{IN88US=> MVXTRW5ITVJ?
NCI-H2126 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nYSWlEPTB;MD61OlgyPSEQvF2= MYjTRW5ITVJ?
SNU-C2B MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rVOGlEPTB;MD61O|k4PyEQvF2= MkjOV2FPT0WU
DBTRG-05MG M4TTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn0XldyUUN3ME2wMlU5ODV|IN88US=> M{PCZXNCVkeHUh?=
MKN1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnEZXdnUUN3ME2wMlU5Pzh|IN88US=> NFLXXmJUSU6JRWK=
ES3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm1TZRiUUN3ME2wMlU6OTJ2IN88US=> NFjscllUSU6JRWK=
OVCAR-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHKSXJKSzVyPUCuOVk{PDFizszN MUfTRW5ITVJ?
ACHN MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PGdGlEPTB;MD62NFU3QSEQvF2= NWS1NVh4W0GQR1XS
SW872 NHK3cndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHVVpA5UUN3ME2wMlYxPzZ|IN88US=> MlnsV2FPT0WU
CP66-MEL NX3yW2l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\oVHVlUUN3ME2wMlYxQTZ7IN88US=> NVH4O2hDW0GQR1XS
NCI-H661 M2[4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:3So1{UUN3ME2wMlYyOTB2IN88US=> M3TaS3NCVkeHUh?=
UACC-893 NULDSJRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvyenlKSzVyPUCuOlM3QDFizszN MULTRW5ITVJ?
JVM-3 NHrEc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwNkO4NFQh|ryP M4\oVXNCVkeHUh?=
SF268 NVnIe3J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\BeotKSzVyPUCuOlQ{PDlizszN NXHRSWRPW0GQR1XS
OCI-AML2 NHq1TnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwNkWzPVch|ryP MkjIV2FPT0WU
RPMI-8226 MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Hw[WlEPTB;MD62OlMzOyEQvF2= NIXyfG9USU6JRWK=
MKN28 Mo\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\DSmlEPTB;MD62OlYzPCEQvF2= NVThZYM{W0GQR1XS
MDA-MB-453 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHFTWM2OD1yLk[3NVgh|ryP MYHTRW5ITVJ?
BV-173 M3S1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHDdnlTUUN3ME2wMlY5Pjd7IN88US=> M37CcHNCVkeHUh?=
NCI-H358 MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;4TWM2OD1yLk[4O|I3KM7:TR?= M1;iWXNCVkeHUh?=
NCI-H1651 MnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\wfmlEPTB;MD63JO69VQ>? NYTabVlkW0GQR1XS
MDA-MB-415 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M364c2lEPTB;MD63NFgzQSEQvF2= NVP3OYxPW0GQR1XS
8305C NUXkfm9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPubHlKSzVyPUCuO|I1QThizszN NYjReFdGW0GQR1XS
EFM-19 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnVTWM2OD1yLkezOlcyKM7:TR?= MV\TRW5ITVJ?
RERF-LC-MS MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwN{S2NVMh|ryP NHrZ[JdUSU6JRWK=
A388 NVzzTWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f3bWlEPTB;MD63OlQ3PyEQvF2= NGPmbXVUSU6JRWK=
GI-ME-N Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu0TWM2OD1yLke3NlM2KM7:TR?= MUnTRW5ITVJ?
IGR-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnOwTWM2OD1yLke5NFQ{KM7:TR?= MVHTRW5ITVJ?
LNCaP-Clone-FGC MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfPN4VCUUN3ME2wMlgxODB2IN88US=> Mn3HV2FPT0WU
SK-MEL-3 NIfrRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS0TWM2OD1yLkixOVA5KM7:TR?= MmThV2FPT0WU
UACC-257 NFTFWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOyb3l5UUN3ME2wMlgzOjNzIN88US=> MYXTRW5ITVJ?
OE33 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTYNphuUUN3ME2wMlg2OTBzIN88US=> NYPFeolIW0GQR1XS
QIMR-WIL M{\pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVOwXWZCUUN3ME2wMlg2OTRzIN88US=> NGq4V5BUSU6JRWK=
NCI-H2009 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[zTWM2OD1yLki1N|EyKM7:TR?= Mn;3V2FPT0WU
NCI-H522 NITRXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVOwWoIyUUN3ME2wMlg4Pzh|IN88US=> MYnTRW5ITVJ?
Saos-2 M1XYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj2[FB[UUN3ME2wMlg4QDdzIN88US=> MUjTRW5ITVJ?
NB17 NY\DdIJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDhclNJUUN3ME2wMlg5ODJ3IN88US=> NIjWW2tUSU6JRWK=
D-392MG MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DnOWlEPTB;MD64PVM2PiEQvF2= MkfuV2FPT0WU
SHP-77 NVztVI5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwOUC0PFUh|ryP NHPRUZJUSU6JRWK=
SK-MEL-30 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwOUGxPFUh|ryP MXjTRW5ITVJ?
GCIY NX[3c3NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwOUG4OFMh|ryP MnzMV2FPT0WU
HCC70 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfwfIJ3UUN3ME2wMlkzODV7IN88US=> M1HEU3NCVkeHUh?=
LU-65 M{HvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLuNnlVUUN3ME2wMlkzPTlzIN88US=> MXTTRW5ITVJ?
NCI-H1563 MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HmcWlEPTB;MD65OFg3PSEQvF2= M4TSeXNCVkeHUh?=
KURAMOCHI NEHseVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7YeZo6UUN3ME2wMlk2OTl{IN88US=> NVG4VoZTW0GQR1XS
PA-1 M1jNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDHTWM2OD1yLkm1OFI1KM7:TR?= M2XtUnNCVkeHUh?=
NOS-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDxTWM2OD1yLkm3OFg6KM7:TR?= M2X5RnNCVkeHUh?=
NCI-H69 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwOUe2N|Qh|ryP NHv6d3ZUSU6JRWK=
KYSE-450 NV;ibGlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jvUWlEPTB;MD65PFYzPiEQvF2= NITLXG9USU6JRWK=
8505C MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwOUm5PFIh|ryP M1i0SXNCVkeHUh?=
TGBC24TKB MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz0U5pKSzVyPUGuNFAxQDRizszN MorGV2FPT0WU
PFSK-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfNXHNIUUN3ME2xMlAyPDJ6IN88US=> M4O1ZnNCVkeHUh?=
EKVX NY\GfYxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIOyT2tKSzVyPUGuNFMyOjFizszN M2PsPHNCVkeHUh?=
RCM-1 MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwMEW1NFch|ryP NULVSW86W0GQR1XS
SW900 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPSPGtvUUN3ME2xMlA4QDNizszN M2XjRnNCVkeHUh?=
D-542MG MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHh[3dLUUN3ME2xMlA4QDV3IN88US=> MkXtV2FPT0WU
SK-PN-DW NYPIV2gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwMUCwOVYh|ryP MUnTRW5ITVJ?
NCI-H727 M1TXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH6w[oVKSzVyPUGuNVAyPTRizszN NWjYTXk1W0GQR1XS
SW837 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfMTWM2OD1zLkGwPVU1KM7:TR?= M2nseHNCVkeHUh?=
BT-20 NIXp[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPtTWM2OD1zLkGxNlA1KM7:TR?= MX7TRW5ITVJ?
RH-18 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjZZotKSzVyPUGuNVMyODNizszN Mk\RV2FPT0WU
TE-12 NXHDS4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rpZmlEPTB;MT6xN|M{OyEQvF2= MWDTRW5ITVJ?
NB10 NGTpRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzFZZZ5UUN3ME2xMlE{OzR2IN88US=> MVTTRW5ITVJ?
AU565 NVXkfo1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LiVWlEPTB;MT6xOVk4OyEQvF2= MlXYV2FPT0WU
OAW-42 NVvhdY5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfiSoFnUUN3ME2xMlE5OzB4IN88US=> MoPSV2FPT0WU
DJM-1 NIL6bHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rx[mlEPTB;MT6xPVg5OSEQvF2= NYG5OmVGW0GQR1XS
HH M2O2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm2bXlKSzVyPUGuNlM5OzFizszN MknOV2FPT0WU
LAMA-84 NHqxVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jwVWlEPTB;MT6yO|M6PCEQvF2= Mn2zV2FPT0WU
KNS-42 M4T1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfFTWM2OD1zLkOwNlk3KM7:TR?= M4HsSnNCVkeHUh?=
NCI-H2052 NEPoNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD6TWM2OD1zLkOwOVA4KM7:TR?= M4\YZXNCVkeHUh?=
MLMA M{HwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rQVWlEPTB;MT6zNlQxPyEQvF2= MkX0V2FPT0WU
NB12 M1L1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq2eVZKSzVyPUGuN|U3OzZizszN NHnIWFFUSU6JRWK=
NCI-H1838 M1K3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fHemlEPTB;MT6zOlMxPiEQvF2= NWfZbIoxW0GQR1XS
NCI-H526 NVHlSY5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXDTWM2OD1zLkO3PFU{KM7:TR?= MXrTRW5ITVJ?
LS-123 NH;ob4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P5WmlEPTB;MT6zPVA6PCEQvF2= NFfC[5VUSU6JRWK=
HDLM-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFwM{myO|Eh|ryP NFXVNGNUSU6JRWK=
MC-IXC Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnzTWM2OD1zLkSyN|cyKM7:TR?= NF7NTHpUSU6JRWK=
HCT-15 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwNEOwOlgh|ryP NY\neWpKW0GQR1XS
NCI-H596 M4nQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFwNEWwOlEh|ryP NVfEOohjW0GQR1XS
ZR-75-30 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3vR2lRUUN3ME2xMlQ4ODh{IN88US=> NFLTXoxUSU6JRWK=
A704 MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnkTWM2OD1zLk[2OVY{KM7:TR?= MV\TRW5ITVJ?
OVCAR-4 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnJT|ZKSzVyPUGuOlk3ODdizszN NXnOVlNwW0GQR1XS
SW1417 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\tb|RKSzVyPUGuO|I5PDlizszN MYLTRW5ITVJ?
CAS-1 NXPRSFZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrybFhKSzVyPUGuO|M6OzZizszN MmrFV2FPT0WU
IST-SL1 M2L4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXkTWM2OD1zLke5O|U6KM7:TR?= NYLwU2VHW0GQR1XS
A253 NVW1Wo83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DKb2lEPTB;MT64NlI{QSEQvF2= NHj1fZRUSU6JRWK=
EW-16 Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfCPW5KSzVyPUGuPFI5PzVizszN NX;hWXdJW0GQR1XS
SK-NEP-1 MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfOWnhyUUN3ME2xMlg3QTh6IN88US=> M4DMU3NCVkeHUh?=
NCI-H226 NH;a[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwOEmzOVkh|ryP NFLEZ|RUSU6JRWK=
HOP-92 M4jxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTRSpR7UUN3ME2xMlk3ODl7IN88US=> MUjTRW5ITVJ?
NCI-H441 M2LOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJwMEKzN|ch|ryP NGO4S5NUSU6JRWK=
LU-139 NFLNbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PQbWlEPTB;Mj6wN|EyPCEQvF2= M{K4enNCVkeHUh?=
SJRH30 NFLITpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJwMESyOVMh|ryP MXTTRW5ITVJ?
MG-63 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TSTmlEPTB;Mj6xOFEyOSEQvF2= NWrGUFBPW0GQR1XS
NH-12 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJwMUWwNFYh|ryP Ml3vV2FPT0WU
NB7 NXu4VWpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJwMUm2O|Mh|ryP NYnPSJpLW0GQR1XS
LB771-HNC MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJwMkC1PVUh|ryP NGPTcY5USU6JRWK=
HCC1569 M1nxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnUUHYxUUN3ME2yMlI1PTh|IN88US=> MU\TRW5ITVJ?
D-283MED NEjGdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr3W5JKSzVyPUKuNlQ4QDJizszN NHLP[5JUSU6JRWK=
J-RT3-T3-5 M4jjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHlTWM2OD1{LkK1N|UyKM7:TR?= M4TkNXNCVkeHUh?=
ATN-1 NEjKZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\JTWM2OD1{LkOzNFgzKM7:TR?= MkXKV2FPT0WU
HCC1954 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jU[WlEPTB;Mj6zOFQxQCEQvF2= MX7TRW5ITVJ?
SCC-15 NI\4dpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPqXWVlUUN3ME2yMlM6OzF{IN88US=> MXnTRW5ITVJ?
COLO-668 NFPGcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PCZWlEPTB;Mj60N|Ih|ryP NXvve|M4W0GQR1XS
LB373-MEL-D NHqySIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjSTWM2OD1{LkW0Olc4KM7:TR?= MUjTRW5ITVJ?
no-10 NES4WGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Hwb2lEPTB;Mj61OFk1PyEQvF2= NYi2S2hZW0GQR1XS
HT-1197 NXHoOlM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;OWmJrUUN3ME2yMlY{OTh6IN88US=> M2K1R3NCVkeHUh?=
DU-145 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\zOItKSzVyPUKuO|kyPjJizszN NVzSdHM1W0GQR1XS
SK-N-AS NFvyO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHITWM2OD1{Lki0OlkzKM7:TR?= M2PzVHNCVkeHUh?=
MOLT-4 M3jxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\NVmlEPTB;Mj64OVMzOiEQvF2= NHi2cnRUSU6JRWK=
EW-22 M{HHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Xv[2lEPTB;Mj65Nlg1OSEQvF2= M{nkU3NCVkeHUh?=
DB NGriOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPvNmtVUUN3ME2yMlk4PzV7IN88US=> MmGyV2FPT0WU
HL-60 NVHDfVRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTNwMESzO|Yh|ryP MlrzV2FPT0WU
SK-N-DZ Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Xk[WlEPTB;Mz6wOVA4PSEQvF2= MYHTRW5ITVJ?
NY NFvGR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfwTWM2OD1|LkC4OVQzKM7:TR?= NIDwOJlUSU6JRWK=
T47D NHXLeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfLRmlKSzVyPUOuNVA2PThizszN MYXTRW5ITVJ?
NCI-H2029 NVHCT3M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXGSpNKSzVyPUOuNlI1PzdizszN NHLNVmdUSU6JRWK=
KARPAS-299 MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm3R2lIUUN3ME2zMlI3ODJ5IN88US=> NYLZV3NUW0GQR1XS
KM-H2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXTdpdKSzVyPUOuN|A3QCEQvF2= NFvrTHJUSU6JRWK=
CHP-134 NXTRbGxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LnRmlEPTB;Mz60O|M6KM7:TR?= M2nHbnNCVkeHUh?=
22RV1 NGqzO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDFSW5wUUN3ME2zMlQ6OTZ6IN88US=> M3\vXXNCVkeHUh?=
NB5 M{fzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNwNUC2PFkh|ryP M3nJcXNCVkeHUh?=
CW-2 NVjLO4htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XpU2lEPTB;Mz61OVMyPCEQvF2= NHzDdVRUSU6JRWK=
EFO-21 M3rsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX2TWM2OD1|LkW2PVQh|ryP M1WyTHNCVkeHUh?=
HuH-7 NF7vSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXFRXFKSzVyPUOuOVg1OTRizszN NHj2Z4RUSU6JRWK=
ALL-PO NHzGW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vTcGlEPTB;Mz62NlM{PSEQvF2= NIe2VnhUSU6JRWK=
EM-2 M4LONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXkTWM2OD1|Lk[5NFEyKM7:TR?= MWLTRW5ITVJ?
KLE NX2zeVdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rNSWlEPTB;Mz63N|AzQSEQvF2= MXvTRW5ITVJ?
NEC8 M2jaNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInqWJBKSzVyPUOuPVE5ODhizszN MlzwV2FPT0WU
KP-N-YN MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36yemlEPTB;Mz65N|Q4PiEQvF2= MYjTRW5ITVJ?
SK-MEL-1 M4XJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXiTWM2OD12LkCzOVE5KM7:TR?= M1z2OXNCVkeHUh?=
CAL-54 NVzxflMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjwTWM2OD12LkC1PVEh|ryP NIXqWlBUSU6JRWK=
MS-1 M3nlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXtR|BKSzVyPUSuNVYyPTVizszN M2[ySHNCVkeHUh?=
NCI-H209 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTRwMkm5PVkh|ryP M{XaVnNCVkeHUh?=
NOMO-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i1PWlEPTB;ND6zNlE{OSEQvF2= MUXTRW5ITVJ?
RPMI-2650 M135d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTRwM{[zNlch|ryP MmXTV2FPT0WU
NCI-H810 NW\xSldWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Pac2lEPTB;ND6zPVc{PiEQvF2= MVfTRW5ITVJ?
Ca9-22 NHrtbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzkNnNKSzVyPUSuOFU3QTFizszN Ml[4V2FPT0WU
ES4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KxOGlEPTB;ND60O|A6PSEQvF2= M1XDNnNCVkeHUh?=
ES6 NIjXWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LGdmlEPTB;ND60PVY2PyEQvF2= M3rGeHNCVkeHUh?=
DMS-114 M1fGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRwNUS2PVEh|ryP NUDadXF6W0GQR1XS
ONS-76 NUWwPYxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDPSVVTUUN3ME20MlU4QTVizszN MnLSV2FPT0WU
K-562 M{X2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTRwN{O4NVQh|ryP Mn\TV2FPT0WU
MHH-NB-11 NWPDe5VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfl[Xh{UUN3ME20Mlc2PDZzIN88US=> NUHo[lFRW0GQR1XS
Calu-3 MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WzPWlEPTB;ND63PFU1QCEQvF2= MlS3V2FPT0WU
HT55 M2nI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTRwOES1OFUh|ryP MoPBV2FPT0WU
SK-N-FI M1\hUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGySYhDUUN3ME20Mlg2ODB7IN88US=> NUDhV4dTW0GQR1XS
ES1 NGLkSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jzRWlEPTB;ND64OlA2PyEQvF2= M2PacXNCVkeHUh?=
SF126 NXiyR4NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXSNoxKSzVyPUSuPVMyQDRizszN NXvVTFBkW0GQR1XS
ES5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWxNIEyUUN3ME21MlEzPDJ5IN88US=> Mmf6V2FPT0WU
LoVo NFOyOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O3SWlEPTB;NT6xOVg4OSEQvF2= M{juZ3NCVkeHUh?=
SNU-387 NHXvNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTVwM{KzN|kh|ryP M1TmOXNCVkeHUh?=
C8166 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi4dZV3UUN3ME21MlM3OzN7IN88US=> MWPTRW5ITVJ?
LS-1034 NHTZcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi5dnFbUUN3ME21MlQzOzB5IN88US=> NYnlblE{W0GQR1XS
GR-ST M{XwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7RXIx1UUN3ME21MlUzOjBzIN88US=> MoPnV2FPT0WU
NCI-H1092 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfhOHZVUUN3ME21MlczQDR|IN88US=> M2nxU3NCVkeHUh?=
647-V M1LPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTVwN{S3NFYh|ryP MkPKV2FPT0WU
EW-13 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHrTWM2OD13Lke2OlI4KM7:TR?= NECyVGNUSU6JRWK=
KGN Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTZwMEm5NlEh|ryP MoL4V2FPT0WU
D-423MG Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTZwNECyPFQh|ryP MUHTRW5ITVJ?
ECC10 M1;BVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjVS2g3UUN3ME23MlExOTBzIN88US=> M2HDZ3NCVkeHUh?=
TE-5 NXzycYtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXjR5RKSzVyPUeuOFEzQThizszN M37NfnNCVkeHUh?=
P12-ICHIKAWA M1zzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P4fGlEPTB;Nz60OVUzOyEQvF2= Ml70V2FPT0WU
NCI-H82 M2HMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHrTWM2OD15LkS1O|AyKM7:TR?= M{HGdnNCVkeHUh?=
NCI-H1993 NH33bIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjhUnNYUUN3ME23Mlg{ODZ|IN88US=> NGqwcGVUSU6JRWK=
RH-1 NYS3W4ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK3TWM2OD15Lki1NlQ1KM7:TR?= MVnTRW5ITVJ?
SW948 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTdwOU[wOFkh|ryP MYDTRW5ITVJ?
CAL-33 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7V[|U2UUN3ME23Mlk6QTN6IN88US=> NG\GU2FUSU6JRWK=
U-266 NXPET4hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRThwMUW3O|ch|ryP MlT4V2FPT0WU
CAL-72 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRThwMkCzNkDPxE1? M{HJdXNCVkeHUh?=
SNU-423 NXm1OVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTlwM{[2OlYh|ryP MWHTRW5ITVJ?
KG-1 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nOb2lEPTB;OT61PFQ2PiEQvF2= NVjudWtPW0GQR1XS
HCC1395 M4DnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT1ZXNKSzVyPUmuPVI{PTJizszN NIPKW|dUSU6JRWK=
BE-13 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XqOWlEPTB;MUCuPFg6OiEQvF2= NF3sd2VUSU6JRWK=
MKN7 NHOwcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW1RmlDUUN3ME2xNE46PzZ3IN88US=> NVTlZ5FXW0GQR1XS
697 NFjCe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO3R45KSzVyPUGxMlE1PzJizszN NWqyWoxuW0GQR1XS
LU-135 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnEOXBKSzVyPUGxMlI{ODdizszN Mlz3V2FPT0WU
ES7 NV;zRph3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jnPGlEPTB;MUGuN|MyOyEQvF2= MYfTRW5ITVJ?
SK-HEP-1 NUnMO3BHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDrTWM2OD1zMT63OlQ3KM7:TR?= NIXUd3VUSU6JRWK=
BEN NXP1Sog6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXjcWNKSzVyPUGxMlg2OSEQvF2= MXzTRW5ITVJ?
NCI-H1770 M4H6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S0fmlEPTB;MUKuNVI3KM7:TR?= NV7oc4NRW0GQR1XS
SW13 NELCOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF{LkG1OFEh|ryP M{nqNHNCVkeHUh?=
MZ1-PC M4LvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfwTWM2OD1zMj61OFUzKM7:TR?= NYPtfFkxW0GQR1XS
Mo-T MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFewOnZKSzVyPUGyMlc1OjFizszN MYTTRW5ITVJ?
HLE M1zhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLaS|B[UUN3ME2xNk45OjF3IN88US=> MVzTRW5ITVJ?
RCC10RGB MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDRcmpzUUN3ME2xN{43PzFizszN M1fYeHNCVkeHUh?=
COLO-320-HSR NELZcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluwTWM2OD1zMz63N|gyKM7:TR?= MmD0V2FPT0WU
BHT-101 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF|LkizOFUh|ryP NVnvPWQzW0GQR1XS
OCUB-M MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHaTWM2OD1zND6xOlAzKM7:TR?= NX;od3R5W0GQR1XS
MEG-01 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPFTWM2OD1zND6zO|A5KM7:TR?= MYHTRW5ITVJ?
RS4-11 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrkUlZKSzVyPUG0Mlc1OiEQvF2= M1vwbXNCVkeHUh?=
MN-60 M{nBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\sTWM2OD1zND63PFk1KM7:TR?= M4LDfHNCVkeHUh?=
NCI-H1304 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnQXG0xUUN3ME2xOU4xPDJ3IN88US=> NH7jNFNUSU6JRWK=
Ramos-2G6-4C10 NHTXUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF3LkC1PFEh|ryP NV3xO21HW0GQR1XS
NCI-H2342 NIfINItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF3LkKwOFQh|ryP Ml;2V2FPT0WU
LAN-6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXBR2xKSzVyPUG1MlQ1OTRizszN NFzi[I5USU6JRWK=
JVM-2 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfsfGpsUUN3ME2xOU42PzR6IN88US=> MkTiV2FPT0WU
P30-OHK NUDjNIV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjudYw1UUN3ME2xOk4xPjF2IN88US=> MYnTRW5ITVJ?
C-33-A MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\uR29KSzVyPUG2MlYzOTRizszN MoD4V2FPT0WU
RPMI-8866 NH\PPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnexTWM2OD1zNj64OFk3KM7:TR?= NGG4SpFUSU6JRWK=
NCI-H630 NVfONZVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DHcmlEPTB;MU[uPFU{PyEQvF2= MVjTRW5ITVJ?
KYSE-140 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPPTWM2OD1zNz6yNFI5KM7:TR?= NX;mWZp2W0GQR1XS
T84 NF7JN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILIcVJKSzVyPUG4Mlg3QTVizszN NFj0ZYhUSU6JRWK=
KU-19-19 MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjGTWM2OD1zOD65OlA5KM7:TR?= MlPaV2FPT0WU
BALL-1 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHETJBKSzVyPUG5MlM{QTlizszN NISwT4JUSU6JRWK=
Calu-6 NVizSJVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rXemlEPTB;MUmuOFkzKM7:TR?= NHjFR4VUSU6JRWK=
EGI-1 NILmZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF7LkW5PEDPxE1? MmTiV2FPT0WU
MFH-ino M3WyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrkTWM2OD1zOT63OFU1KM7:TR?= Mm\0V2FPT0WU
GB-1 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrrTWM2OD1{MD6zOVM2KM7:TR?= MnnKV2FPT0WU
NCI-H1693 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7Id|BJUUN3ME2yNE43PTB3IN88US=> NV\pfY5mW0GQR1XS
SW1116 NU\u[4tmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jZeGlEPTB;MkCuPVM3OiEQvF2= NVu4VHR7W0GQR1XS
H-EMC-SS M4DWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWeyPW9KUUN3ME2yNk4xPDVizszN NWHUcWppW0GQR1XS
D-502MG NI\HclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LrTmlEPTB;MkKuPFI3OSEQvF2= M2T2XHNCVkeHUh?=
IA-LM M3nsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJ|LkK0PVMh|ryP MVHTRW5ITVJ?
SW1463 NEjJRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD4OFJKSzVyPUKzMlc6KM7:TR?= M2fwSXNCVkeHUh?=
JAR MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJ2LkOyPVMh|ryP NVK5bplbW0GQR1XS
HT NFe4O3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ2LkS3OVMh|ryP M3jY[XNCVkeHUh?=
LCLC-103H NX7XTGd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjPTWM2OD1{ND64OFQ6KM7:TR?= M3HDc3NCVkeHUh?=
SNU-449 M{\3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jYT2lEPTB;MkSuPFc1OSEQvF2= M4\CcXNCVkeHUh?=
KE-37 Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jORWlEPTB;MkWuNFkzQCEQvF2= NF3KSopUSU6JRWK=
NCI-H1623 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPXTWM2OD1{Nz6xN|A{KM7:TR?= NGDqT3dUSU6JRWK=
MOLT-13 NX7tTo1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ5LkO1NVYh|ryP NInZNmZUSU6JRWK=
COLO-741 MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDvTWM2OD1|MT6zN|M{KM7:TR?= MVvTRW5ITVJ?
NB6 NHixSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG4Z|U4UUN3ME2zNk4zQDd4IN88US=> M4DrXnNCVkeHUh?=
MOLT-16 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PuXGlEPTB;M{OuNFA2PSEQvF2= NGG0coFUSU6JRWK=
IST-MES1 NUTiVINKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTQTWM2OD1|ND6wOVQyKM7:TR?= NFzsenFUSU6JRWK=
A4-Fuk NX7XZ5lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN3LkC2OkDPxE1? NEDMbpNUSU6JRWK=
CAL-85-1 NX\IOHBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTN3LkK4NVch|ryP M4rrPHNCVkeHUh?=
CCRF-CEM MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTN5LkG1N|Yh|ryP NGqxOnBUSU6JRWK=
HAL-01 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLmXnlIUUN3ME2zPE41QDh7IN88US=> M4q4WHNCVkeHUh?=
HEL M1u2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;XXnpKSzVyPUSzMlM1ODlizszN NVLLb2p6W0GQR1XS
EW-1 NIjEXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\PSnZKSzVyPUSzMlQ4PjhizszN M{LzOXNCVkeHUh?=
MDA-MB-231 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\HVmRQUUN3ME20OU4yOTl7IN88US=> NEOyZY1USU6JRWK=
ABC-1 M2rnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTre5FFUUN3ME20Ok45PTN6IN88US=> MX\TRW5ITVJ?
NCI-H446 NEDROGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO3TWM2OD12OD61NFU5KM7:TR?= NVPPZWlHW0GQR1XS
MHH-PREB-1 NHWwOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfFN4JKSzVyPUS5MlYxODdizszN MnjPV2FPT0WU
DOHH-2 NIDLb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfmdYFKSzVyPUS5MlY3PTZizszN MnXVV2FPT0WU
GCT MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLO[5JKSzVyPUS5MlY6PzZizszN NYH4[|J[W0GQR1XS

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; 

PubMed: 20090920     


Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control.

EGFR / PDGFR / AKT / MAPK / c-RAS; 

PubMed: 18682579     


17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment.

pAKT / pMAPK / pRb; 

PubMed: 18682579     


The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment.

Cleaved PARP / Survivin; 

PubMed: 18827603     


Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control.

LATS1 / p-LATS1 / YAP / CTGF; 

PubMed: 25712415     


Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF.  The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.

20090920 18682579 18827603 25712415
Immunofluorescence
STAT3; 

PubMed: 27279418     


Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole.

YAP / TAZ; 

PubMed: 25290150     


Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM).

β-catenin / E-cadherin; 

PubMed: 25290150     


Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.

27279418 25290150
Growth inhibition assay
Cell viability; 

PubMed: 18682579     


17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.

18682579
体内研究 17-AAG作用于携带3T3-src, B16或CT26移植瘤裸鼠，与Hsp90结合具有高亲和力，IC50为8-35 nM，而作用于正常组织时，IC50为200-600 nM。[1] 17-AAG按50 mg/kg左右剂量处理，引起AR, HER2, HER3, 和 Akt表达明显降低，降低达50%以上，这种作用存在剂量依赖性，结果导致雄激素依赖型 (CWR22)和非依赖型(CWR22R 和CWRSA6) 前列腺移植瘤生长受抑制，抑制率分别为67%, 80%和 68%。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[1]
- 合并

Hsp90结合实验:

纯化的Hsp90蛋白或过量表达HER-2的癌细胞(BT474, N87, SKOV3 和 SKBR3) 裂解物或BT474乳腺癌细胞溶于溶解buffer(20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) ，与不同浓度17-AAG在4oC下温育30分钟，然后和生物素-GM链接的BioMag链霉亲和素磁珠在4oC下温育1小时。试管放置于磁架上,除去未结合的上清液。在溶解buffer中清洗三次磁珠，然后在SDS–PAGE 样本缓冲液中在95oC下加热5分钟。在SDS蛋白凝胶上进行样本分析,使用特点抗体进行Western Blotting。使用Bio-rad Fluor-S 多重图像测量Western Blot条带，计算抑制Hsp90与生物素-GM结合的百分数。测定IC50。
细胞实验：[1]
- 合并
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, 和 PBMC
  • Concentrations: 溶于DMSO, 终浓度为10 μM 左右
  • Incubation Time: 5天
  • Method: 细胞按每孔2000个接种在96孔板上，终培养体积为100 μL，培养24小时， 然后加入浓度不断增高的17-AAG，温育5天。使用 Celltiter 96 AQueous 非放射性细胞增殖检测试剂盒测定存活细胞数。测定IC50。
    (Only for Reference)
动物实验：[2]
- 合并
  • Animal Models: 皮下注射雄激素依赖性CWR22移植瘤的雄性 nu/nu 无胸腺小鼠， 皮下注射雄激素非依赖性的CWR22R和CWRSA6移植瘤的雌性nu/nu 无胸腺小鼠。
  • Dosages: 50 mg/kg 左右
  • Administration: 腹膜注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (170.73 mM)
Water Insoluble
Ethanol '5 mg/mL
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5%DMSO+corn oil
 10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 585.69
化学式

C31H43N3O8
CAS号 75747-14-7
储存条件 粉状
溶于溶剂
别名 CP127374,NSC-330507, KOS 953

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00103272 Terminated Drug: tanespimycin|Drug: bortezomib Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00098488 Terminated Drug: tanespimycin|Biological: rituximab B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00118248 Completed Drug: tanespimycin Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma National Cancer Institute (NCI) December 2004 Phase 2
NCT00098423 Completed Drug: tanespimycin|Drug: cytarabine Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes National Cancer Institute (NCI) November 2004 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • 回答：

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

Selleck产品目录册

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

  • 选择性强的HSP90抑制剂

    NVP-BEP800 : HSP90β-selective, IC50=58 nM.

  • 活性最高的HSP90抑制剂

    KW-2478 : HSP90, IC50=3.8 nM.

  • 用于临床的HSP90抑制剂

    17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.

  • 最新的HSP90抑制剂

    XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

相关HSP (e.g. HSP90)产品

  • PU-H71 New

    PU-H71是有效的选择性HSP90抑制剂，IC50为51 nM。

  • KNK437 New

    KNK437 是一种泛-HSP 抑制剂，其抑制诱导型HSPs，包括 HSP105，HSP72，和 HSP40的合成。

  • VER155008 New

    VER-155008是一种有效的Hsp70家族抑制剂，无细胞试验中对HSP70，HSC70，和 GRP78的IC50分别为0.5 μM，2.6 μM，和 2.6 μM，比作用于HSP90选择性高100多倍。

  • Luminespib (NVP-AUY922)

    Luminespib (AUY-922, NVP-AUY922)是一种高效的HSP90抑制剂，无细胞试验中作用于HSP90α/β的IC50为13 nM /21 nM，对HSP90家族成员GRP94和TRAP-1具有稍弱的作用，与任何小分子HSP90配体均可紧密结合。Luminespib (AUY-922, NVP-AUY922)可有效下调并使IGF-1Rβ蛋白不稳定，从而导致抑制生长、自噬和凋亡。Phase 2。

  • Ganetespib (STA-9090)

    Ganetespib (STA-9090)是一种HSP90抑制剂，在OSA 8种细胞中IC50为4 nM，诱导OSA细胞凋亡，而不影响正常的成骨细胞；是STA-1474的活性代谢物。Phase 3。

  • Alvespimycin (17-DMAG) HCl

    Alvespimycin (17-DMAG) HCl是一种有效的HSP90抑制剂，无细胞试验中IC50为62 nM。 Phase 2。

    Features:17-DMAG是抗生素Geldanamycin 的合成衍生物，比现有抗生素具有较低的肝毒性，比相似衍生物17-AAG效果和有效性更强。

  • Geldanamycin

    Geldanamycin是一种天然的HSP90抑制剂，Kd为1.2 μM，特异性干扰糖皮质激素受体（GR）/HSP联合。

  • HSP990 (NVP-HSP990)

    NVP-HSP990（HSP990）是一种新型有效的选择性 HSP90抑制剂，对HSP90α/β的IC50分别为0.6 nM和0.8 nM。NVP-HSP990可诱导细胞周期阻滞和凋亡。

  • Elesclomol (STA-4783)

    Elesclomol (STA-4783)是一种新型有效的oxidative stress诱导剂，在肿瘤细胞中引起促凋亡作用。Phase 3。

  • Onalespib (AT13387)

    Onalespib (AT13387)是一种有效的，选择性Hsp90抑制剂，在A375细胞中IC50为18 nM，具有长持续性抗肿瘤活性。Phase 2。

Tags: 购买Tanespimycin (17-AAG) | Tanespimycin (17-AAG)供应商 | 采购Tanespimycin (17-AAG) | Tanespimycin (17-AAG)价格 | Tanespimycin (17-AAG)生产 | 订购Tanespimycin (17-AAG) | Tanespimycin (17-AAG)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID